Spots Global Cancer Trial Database for Identification of Predictive and Prognostic Markers for Lung Cancer With Metastases

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Identification of Predictive and Prognostic Markers for Lung Cancer With Metastases

Official Title: Identification of Predictive and Prognostic Markers for Lung Cancer With Metastases

Study ID: NCT02301858

Conditions

Lung Cancer

Primary Tumor

Metastases

Interventions

Genome analysis of tissue samples.

Study Description

Brief Summary: The project aims to compare the histopathological and molecular characteristics of tumour tissue from metastases with similar analyses of the primary tumour in the lung, where it is available. The investigators will therefore perform analysis of blood samples if possible, to identify predictive markers in blood samples.

Detailed Description: The investigators want to make genome analysis of tissue samples. This involves analysing the RNA, DNA methylation, for example in cancer cells. This will provide information regarding somatic changes in cancer cells, such as mutations. All of the investigators analysis will be cancer-focused, with the goal of increasing understanding of the heterogeneity. The investigators will therefore perform analysis of blood samples if possible, to identify predictive markers in blood samples. This will then be the miRNA, RNA expression or protein expression in blood samples.